LENZ Therapeutics (NASDAQ:LENZ - Free Report) had its price target raised by Raymond James Financial from $39.00 to $40.00 in a research report report published on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.
Other analysts have also recently issued research reports about the stock. Citigroup increased their price target on shares of LENZ Therapeutics from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Thursday. Piper Sandler initiated coverage on LENZ Therapeutics in a research note on Monday, April 14th. They set an "overweight" rating and a $51.00 target price for the company. Finally, HC Wainwright raised their price objective on LENZ Therapeutics from $38.00 to $48.00 and gave the stock a "buy" rating in a research report on Monday, July 28th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $49.60.
View Our Latest Stock Report on LENZ
LENZ Therapeutics Stock Performance
NASDAQ LENZ traded down $0.63 on Thursday, reaching $29.33. 381,899 shares of the company's stock traded hands, compared to its average volume of 357,073. LENZ Therapeutics has a fifty-two week low of $16.53 and a fifty-two week high of $38.93. The stock has a 50 day moving average price of $31.03 and a 200-day moving average price of $27.01. The firm has a market cap of $836.55 million, a price-to-earnings ratio of -15.44 and a beta of 0.42.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.05. The firm had revenue of $5.00 million for the quarter, compared to analysts' expectations of $5.00 million. As a group, equities research analysts anticipate that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On LENZ Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of LENZ. KLP Kapitalforvaltning AS acquired a new stake in shares of LENZ Therapeutics during the fourth quarter worth about $46,000. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after buying an additional 1,151 shares during the period. Virtus ETF Advisers LLC acquired a new position in shares of LENZ Therapeutics in the fourth quarter worth $67,000. Banque Transatlantique SA purchased a new stake in shares of LENZ Therapeutics during the first quarter worth $119,000. Finally, GAMMA Investing LLC increased its position in shares of LENZ Therapeutics by 5,254.1% during the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock worth $150,000 after acquiring an additional 5,727 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access